In Patients with Myeloma Who Postpone HSCT, Quadruplet Displays "Excellent Activity.".

Published Date: 29 Apr 2024

With isatuximab plus KRd, ORR in newly diagnosed disease reaches 90%.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.

2.

RML to develop bone marrow transplantation at Lady Hardinge Medical College in Safdarjung

3.

In a study, immune detection of oral cancers is linked to obesity.

4.

In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.

5.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot